Search

Displaying results 1741 - 1750 of 7535 in total
  1. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.

  2. Drug

    Tropicamide

    go.drugbank.com/drugs/DB00809
    Approved

    Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. … [L32178] Oral tropicamide has been investigated as a potential drug to relieve sialorrhea in patients with Parkinson's Disease.[A229958]

  3. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … continued approval potentially contingent on confirmatory trials.

  4. Drug

    Ferric sulfate

    go.drugbank.com/drugs/DB11171
    Approved

    It is used in different fields such as dermatology, dentistry and it is thought to present hemostatic properties by interacting chemically with blood proteins. … It is produced by the reaction of sulfuric acid and an oxidizing agent.

  5. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as … In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis.

  6. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

  7. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]

  8. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.

  9. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years … Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do

    Mixtures: Emercreme No4 Ont Efa
  10. Drug

    Melatonin

    go.drugbank.com/drugs/DB01065
    ApprovedInvestigationalNutraceuticalVet approved

    ) but outside the blood-brain barrier. … In mammals, melatonin is produced by the pineal gland.

    Synonyms: 5-methoxy-N-acetyl tryptamine, 5-methoxy-N-acetyltryptamine